A new immunotherapy, using genetically modified T-cells, significantly extends the lives of solid tumor patients.
Clinical trials demonstrate a remarkable 40% increase in survival time for those with advanced gastric cancer.
This innovative Car T-cell therapy targets and destroys cancer cells, offering hope for a broader range of cancers.
Experts hail this as a major breakthrough, potentially revolutionizing treatment and improving patient outcomes significantly.
